dexamethasone
dexamethasone: sourced relationships with 2 companies · 212 clinical trials tracked · 2 FDA decisions.
dexamethasone evidence translation
What we can confirm
2 FDA records · 212 tracked trials
What it means
What to watch
Prepared research question
What is verified about dexamethasone, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 11 study sponsors
Related indications
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| AbbVie Inc. (ABBV) Reported 2009-06-17 · Current development: unknownSource | Approved |
| OCULAR THERAPEUTIX, INC (OCUL) Reported 2018-11-30 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (212)showing 10 most recent
A Phase 1 Study of the RAGE Inhibitor FPS-ZM1 for Controlling Post-Operative Cerebral Edema in Glioblastoma Patients
Primary endpoint: RAGE Antagonist FPS-ZM1 (FPS-ZM1) related adverse events
A Randomized Phase II/III Trial Evaluating Bipolar Androgen Therapy Followed by Darolutamide vs. Standard of Care in Patients With Metastatic Castration Resistant Prostate Cancer
Primary endpoint: Second progression-free survival (PFS2) (Phase II)
An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor
Primary endpoint: Superiority of progression free survival (PFS)
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Primary endpoint: Safety Run-In: Number of Participants With Adverse Events (AE)s
A Phase 3 Multicenter, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) Compared to Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (Dara-CyBorD) in Subjects With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Primary endpoint: Number of Participants With Adverse Events
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors
Primary endpoint: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0
A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)
Primary endpoint: Dose limiting toxicities (Safety run-in: Cohort A)
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
Primary endpoint: Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of MK-2010 in Combination With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)
Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Primary endpoint: Safety of Golcadomide + Pemetrexed, Rituximab and Dexamethasone
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with dexamethasone?
dexamethasone has dated SEC/FDA relationship records for AbbVie Inc., OCULAR THERAPEUTIX, INC.
How many clinical trials involve dexamethasone?
BioSniper tracks 212 clinical trials involving dexamethasone.
What is dexamethasone's latest FDA decision?
The most recent tracked FDA decision for dexamethasone is Approval for 1 INDICATIONS AND USAGE DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). 1.1 Ocular Inflammation and Pain Following Ophthalmic Surgery DEXTENZA is indicated for the treatment of ocular inflammation and pain following ophthalmic surgery ( 1.1 ). 1.2 Itching Associated with Allergic Conjunctivitis DEXTENZA is indicated for the treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older ( 1.2 ). Limitations of Use The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure [see Use in Specific Populations ( 8.4 )] ., dated November 30, 2018.